Tega Industries Q1 FY27 Results Analysis: Normalized PAT Jumps 158%, Molycop Debut Above Guidance
Cofacto Research
Updated August 14, 2026
2 min read
Positive
Tega Industries Ltd's Q1 FY27 numbers came in strong. Here's a quick read of what worked, what to watch, and what management said.
Quick Details| Results date | August 13, 2026 |
|---|
| Quarter | Q1 FY 2026-2027 |
|---|
| Revenue (Q1) | Rs. 1,723.44 Cr (+383.99% YoY) |
|---|
| PAT (Q1) | Rs. -108.25 Cr |
|---|
| EBITDA margin | 14.30% (-131 bps YoY) |
|---|
| EPS (Q1) | Rs. -11.47 |
|---|
| Market cap | Rs. 12,542.57 Cr |
|---|
| CMP | Rs. 1,669.50 |
|---|
Quarter Snapshot
Strong standalone performance with 60% revenue growth and margin expansion, plus an above-guidance Molycop debut, confirm the core thesis. The reported loss is entirely due to one-time acquisition costs; normalized PAT rose 158% YoY. Equipment segment weakness and elevated finance costs are near-term concerns, but underlying profitability and order conversion remain healthy.
Key Investment Insights
Key Positives
- Standalone revenue grew 60.30% YoY to Rs.268.65 Cr, with EBITDA margin expanding 538 bps to 26.43% (above 21-22% guidance)
- Molycop contributed one-month revenue of Rs.1,291.64 Cr at 13.24% EBITDA margin (above ~12% guidance)
- Consumables Others segment revenue grew 35.08% YoY, confirming conversion of delayed orders
- Normalized PAT-to-owners of Rs.91.28 Cr vs Rs.35.34 Cr YoY, a 158% increase
- Segment EBITDA of Rs.246.53 Cr (14.30% margin) shows underlying operating profitability despite one-time costs
Risk Factors
- Consolidated reported loss of Rs.108.25 Cr due to one-time Molycop acquisition costs of Rs.190.96 Cr
- Equipment segment revenue fell 44.37% YoY and swung to an EBITDA loss of Rs.1.59 Cr, missing 25%+ growth guidance
- Finance costs surged to Rs.116.71 Cr from Rs.6.18 Cr YoY (annualized ~Rs.467 Cr), driven by acquisition debt, pressuring net earnings
- Molycop's lower-margin grinding media mix (13.24% EBITDA) combined with higher finance costs reduces overall profitability
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.
Powered by Cofacto — AI research platform for Indian stocks, every claim cited from primary filings
Login Now